Clinical Evaluation of Safety and Immunogenicity of PADRE-Cytomegalovirus (CMV) and Tetanus-CMV Fusion Peptide Vaccines With or Without PF03512676 Adjuvant

Background. It has been reported that cytomegalovirus (CMV) pp65-specific T cells can protect hematopoietic cell transplant (HCT) recipients from CMV complications. Two candidate CMV peptide vaccines composed of the HLA A*0201 pp65(495-503) cytotoxic CD8(+) T-cell epitope fused to 2 different univer...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: La Rosa, Corinna, Longmate, Jeff, Lacey, Simon F., Kaltcheva, Teodora, Sharan, Rahul, Marsano, Denise, Kwon, Peter, Drake, Jennifer, Williams, Brenda, Denison, Sharon, Broyer, Suenell, Couture, Larry, Nakamura, Ryotaro, Kelsey, Morris I., Krieg, Arthur M., Diamond, Don J., Zaia, John A.
פורמט: Artigo
שפה:Inglês
יצא לאור: Oxford University Press 2012
נושאים:
Major Articles and Brief Reports
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3308906/
https://ncbi.nlm.nih.gov/pubmed/22402037
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jis107
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים